Skip to main content

Table 3 Criteria for prescribing omalizumab fulfilled and good response

From: 4-month omalizumab efficacy outcomes for severe allergic asthma: the Dutch National Omalizumab in Asthma Registry

 

Fulfilled/good response

Not fulfilled/good response

Severe allergic asthma

380/250

12/5

Age >6 years

403/263

0/0

A positive skin test or RAST

364/241

26/12

FEV1 <80

279/183

116/77

>2 exacerbations

384/250

11/7

Maximum dose LABAs and ICS

394/257

4/3